Dr. Moriceau focuses his studies on developing next-generation therapeutics to defeat advanced metastatic melanoma and oversees students at different levels of education.
LOS ANGELES, CA, February 13, 2024 /24-7PressRelease/ -- Gatien Moriceau has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Drawing on years of professional expertise in bone physiology and education, Dr. Moriceau excels as an assistant adjunct professor at the University of California, Los Angeles. Dr. Moriceau focuses his studies on developing next-generation therapeutics to defeat advanced metastatic melanoma and oversees students at different levels of education. Over the years, Dr. Moriceau has authored numerous articles, including "Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Co-targeting but Result in Melanoma Drug Addiction" and "Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity" published in Cancer Cell and Cancer Discovery respectively.
As an expert in his field, Dr. Moriceau earned a Bachelor of Science in Bone Physiology from the University of Paris V in 2007. Subsequently, he expanded on his professional knowledge by completing a PhD with a specialization in bone cancer from the University of Nantes. Dr. Moriceau has been recognized for his innovation with several prestigious awards from several organizations including the Melanoma Research Alliance, and National Institutes of Health.
While his career has been filled with highlights, Dr. Moriceau takes the most pride in publishing an article in 2021 regarding the combination of an equipotent RAF inhibitor (RAFi) with an allosteric MEKi that durably prevents and overcomes acquired resistance in melanoma and another one more recently in which Dr. Moriceau and his colleagues discovered that acquired resistant genomes of metastatic melanoma amplify resistance-driving and resistance-specific amplicons via extrachromosomal circular DNA (ecDNA) and complex genomic rearrangements (CGRs). The cornerstone of his success lies in his love of what he does and his curiosity. Looking toward the future, he intends to experience his career's continued growth and success by opening his therapeutic strategies to other cancer histologies. Ultimately, Dr. Moriceau aims to oversee additional clinical trials for patients with melanoma.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #